Pyronaridine-artesunate (PA)

DRUG2 trials

Sponsors

Liverpool School of Tropical Medicine

Conditions

Covid-19MalariaMalaria (Uncomplicated)Malaria, AntepartumMalaria, Pregnancy

Phase 3

Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

CompletedNCT04695197

Liverpool School of Tropical MedicineCovid-19, Malaria

Start: 2021-01-08End: 2024-02-20Updated: 2024-02-23

Safety of Antimalarials in the FIRst trimEster

RecruitingNCT06962319

Liverpool School of Tropical MedicineMalaria, Antepartum, Malaria, Pregnancy, Malaria (Uncomplicated)

Start: 2025-09-30End: 2029-08-31Target: 1510Updated: 2025-11-19

Related Papers

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV).

2026-01-03